

**PB 39 of 2018**

**National Health (Pharmaceutical Benefits – early supply) Amendment Instrument 2018 (No. 5)**

*National Health Act 1953*

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

I, LISA LA RANCE, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Instrument under subsection 84AAA(2) of the *National Health Act 1953*.

Dated 29 May 2018

**LISA LA RANCE**

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. **Name of Instrument**
2. This Instrument is the *National Health (Pharmaceutical Benefits – early supply) Amendment Instrument 2018 (No. 5)*.
3. This Instrument may also be cited as PB 39 of 2018.
4. **Commencement**

This Instrument commences on 1 June 2018.

1. **Amendment of *National Health (Pharmaceutical Benefits—early supply) Instrument 2015* (PB 120 of 2015)**

Schedule 1 amends the *National Health (Pharmaceutical Benefits—early supply) Instrument 2015* (PB 120 of 2015).

**Schedule 1 Amendments**

1. **Schedule 1, after entry for Cabergoline in the form Tablet 2 mg**

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Cabozantinib | Tablet 20 mg | 20 | 30 | 2 |  |
| Cabozantinib | Tablet 20 mg | 20 | 30 | 5 |  |
| Cabozantinib | Tablet 40 mg | 20 | 30 | 2 |  |
| Cabozantinib | Tablet 40 mg | 20 | 30 | 5 |  |
| Cabozantinib | Tablet 60 mg | 20 | 30 | 2 |  |
| Cabozantinib | Tablet 60 mg | 20 | 30 | 5 |  |

1. **Schedule 1, omit entry for Daclizumab**
2. **Schedule 1, after entry for Donepezil in the form Tablet containing donepezil hydrochloride 5 mg**

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Dulaglutide | Injection 1.5 mg in 0.5 mL single dose pre-filled pen | 20 | 4 | 5 |  |

1. **Schedule 1, after entry for Flutamide**

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Fluticasone furoate with umeclidinium and vilanterol | Powder for oral inhalation in breath actuated device containing fluticasone furoate 100 micrograms with umeclidinium 62.5 micrograms (as bromide) and vilanterol 25 micrograms (as trifenatate) per dose, 30 doses | 20 | 1 | 5 |  |

1. **Schedule 1, after entry for Golimumab in the form Injection 50 mg in 0.5 mL single use pre filled syringe**

*insert:*

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Golimumab | Injection 100 mg in 1 mL single use pre-filled pen | 20 | 1 | 5 |  |